Au-nanoprobes for detection of SNPs associated with antibiotic resistance in Mycobacterium tuberculosis
Au-nanoprobes for detection of SNPs associated with antibiotic resistance in Mycobacterium tuberculosis
复制标题
DOI：
10.1088/0957-4484/21/41/415101
复制
发表时间：
2010-10-15
期刊：
影响因子：
3.5
通讯作者：
Baptista, Pedro V.
中科院分区：
文献类型：
--
作者：
Veigas, Bruno;Machado, Diana;Baptista, Pedro V.
结核病（TB）是人类感染的主要原因之一，在全世界引起高发病率和死亡率。耐多药结核病的新病例率继续增加，由于这些感染很难控制，它们构成了严重的健康问题。在大多数情况下，结核分枝杆菌的耐药性与病原体基因组内几个位点的突变有关。快速，廉价和简单的筛查方法的发展将是至关重要的相关性，这些突变的早期检测，及时有效的诊断和管理MDRTB patient.The使用巯基修饰的寡核苷酸衍生的金纳米粒子（Au-纳米探针）的MDRTB患者的使用是必不可少的分子诊断的新方法。基于Au纳米探针的差异非交联聚集，我们能够开发一种用于检测特定序列的比色方法，并将该方法应用于病原体鉴定和单碱基突变/单核苷酸多态性（SNP）区分。在此，我们报告了用于特异性鉴定RNA聚合酶β亚基内SNP的Au纳米探针的开发（rpoB）基因座是引起95%以上利福平耐药M.结核菌株
Tuberculosis (TB) is one of the leading causes of infection in humans, causing high morbility and mortality all over the world. The rate of new cases of multidrug resistant tuberculosis (MDRTB) continues to increase, and since these infections are very difficult to manage, they constitute a serious health problem. In most cases, drug resistance in Mycobacterium tuberculosis has been related to mutations in several loci within the pathogen's genome. The development of fast, cheap and simple screening methodologies would be of paramount relevance for the early detection of these mutations, essential for the timely and effective diagnosis and management of MDRTB patients.The use of gold nanoparticles derivatized with thiol-modified oligonucleotides (Au-nanoprobes) has led to new approaches in molecular diagnostics. Based on the differential non-cross-linking aggregation of Au-nanoprobes, we were able to develop a colorimetric method for the detection of specific sequences and to apply this approach to pathogen identification and single base mutations/single nucleotide polymorphisms (SNP) discrimination.Here we report on the development of Au-nanoprobes for the specific identification of SNPs within the beta subunit of the RNA polymerase (rpoB locus), responsible for resistance to rifampicin in over 95% of rifampicin resistant M. tuberculosis strains.